Autopsy report · NCT06680661

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

“insufficient funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 5 months before it started.
• Suspended: paused, and may or may not restart.
• 20 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 2

Sponsor

Leland Metheny

Sponsor type

University, hospital or other

Conditions

Acute Myelogenous Leukemia; Acute Lymphatic Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndromes; Myelodysplastic Syndrome Other; Chronic Myelomonocytic Leukemia

Interventions

Cyclophosphamide; Fludarabine; Thiotepa; Total Body Irradiation; Double Umbilical Cord Transplant; Tacrolimus

Participants

20 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• PROactive Evaluation of Function to Avoid CardioToxicity
  “Insufficient funding/staff” (90% match in meaning)
• A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).
  “Unavailable funding” (87% match in meaning)
• Optical Coherence Tomography in Staging Patients With Upper Tract Urothelial Cancer
  “Funding unavailable” (87% match in meaning)
• Hatha Yoga in Breast Cancer Survivors
  “Insufficient staff and funding” (87% match in meaning)
• Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography
  “inadequate funding” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.